Terms: = Bone cancer AND PSA AND Prognosis
162 results:
1. Risk factor analysis and nomogram construction in patients with distant metastatic prostate cancer at different psa levels: a study based on the SEER database.
Li HD; Fan SQ; Qin F; Zhao ST; Kong SP; Ma JG
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2372-2386. PubMed ID: 38567600
[TBL] [Abstract] [Full Text] [Related]
2. [Role of bone Scan Index (BSI) in the prognosis and Treatment Efficacy in Castration-Sensitive Prostate cancer Patients with bone Metastasis].
Deguchi K; Sasaki T; Oue H; Okamoto T; Kato M; Kajiwara S; Higashi S; Masui S; Nishikawa K; Inoue T
Hinyokika Kiyo; 2024 Feb; 70(2):29-37. PubMed ID: 38447942
[TBL] [Abstract] [Full Text] [Related]
3. Pretreatment level of serum sialic acid predicts both qualitative and quantitative bone metastases of prostate cancer.
Sun J; Tian T; Wang N; Jing X; Qiu L; Cui H; Liu Z; Liu J; Yan L; Li D
Front Endocrinol (Lausanne); 2024; 15():1338420. PubMed ID: 38384968
[TBL] [Abstract] [Full Text] [Related]
4. Copy Number Gain in Androgen Receptors Predicts the Poor prognosis in Japanese Castration-resistant Prostate cancer.
Sakamoto S; Ando K; Pae S; Zhao X; Sakai K; Sato K; Saito S; Yamada Y; Rii J; Goto Y; Sazuka T; Imamura Y; Anzai N; Akakura K; Nishio K; Ichikawa T
Anticancer Res; 2024 Feb; 44(2):639-647. PubMed ID: 38307556
[TBL] [Abstract] [Full Text] [Related]
5. Nomogram for predicting the overall survival and cancer-specific survival of patients with intraductal carcinoma of the prostate.
Cui Y; Lin J; Sun D; Zhang H; Diao T; Fu Q
J Cancer Res Clin Oncol; 2024 Jan; 150(2):45. PubMed ID: 38281261
[TBL] [Abstract] [Full Text] [Related]
6. Fluorine-18 prostate-specific membrane antigen-1007-avid indeterminate bone lesions in prostate cancer: clinical and PET/CT features to predict outcomes and prognosis.
Luo L; Wang Z; Wang X; Gao J; Zheng A; Duan X
Clin Radiol; 2024 May; 79(5):346-353. PubMed ID: 38216370
[TBL] [Abstract] [Full Text] [Related]
7. The Prognostic Role of Preoperative PSMA PET/CT in cN0M0 pN+ Prostate cancer: A Multicenter Study.
Marra G; Rajwa P; Filippini C; Ploussard G; Montefusco G; Puche-Sanz I; Olivier J; Zattoni F; Moro FD; Magli A; Dariane C; Affentranger A; Grogg JB; Hermanns T; Chiu PK; Malkiewicz B; Kowalczyk K; Van den Bergh RCN; Shariat SF; Bianchi A; Antonelli A; Gallina S; Berchiche W; Sanchez-Salas R; Cathelineau X; Afferi L; Fankhauser CD; Mattei A; Karnes RJ; Scuderi S; Montorsi F; Briganti A; Deandreis D; Gontero P; Gandaglia G;
Clin Genitourin Cancer; 2024 Apr; 22(2):244-251. PubMed ID: 38155081
[TBL] [Abstract] [Full Text] [Related]
8. The clinical association between coagulation indexes, platelet-related parameters, and bone metastasis of newly diagnosed prostate cancer.
Yu Z; Yuan M; Chen G
Eur J Med Res; 2023 Dec; 28(1):587. PubMed ID: 38093347
[TBL] [Abstract] [Full Text] [Related]
9. Association of WHSC1/NSD2 and T-cell infiltration with prostate cancer metastasis and prognosis.
Li Q; Zhu J; Zhang Y; Pan Y; Li Z; Wang M; Gao Y; Feng D; He X; Zhang C
Sci Rep; 2023 Dec; 13(1):21629. PubMed ID: 38062230
[TBL] [Abstract] [Full Text] [Related]
10. Establishment and assessment of a nomogram for predicting prognosis in bone-metastatic prostate cancer.
Liu W; Wang Z; Wu Y; Li L
Medicine (Baltimore); 2023 Nov; 102(44):e35693. PubMed ID: 37933039
[TBL] [Abstract] [Full Text] [Related]
11. Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate cancer Following Radical Prostatectomy.
Milenkovic U; Kuijk J; Roussel E; Devos G; Van den Broeck T; Van Eecke H; Vanderstichele A; Duvillier T; Verhamme L; Van Haute W; Goeman L; Berghen C; Joniau S; De Meerleer G
Eur Urol Oncol; 2023 Dec; 6(6):582-589. PubMed ID: 36878753
[TBL] [Abstract] [Full Text] [Related]
12. Risk Evaluation of bone Metastases and a Simple Tool for Detecting bone Metastases in Prostate cancer: A Population-Based Study.
Li S; Chen C; Zhu H; Lin Q; Yu Z
Comput Math Methods Med; 2023; 2023():9161763. PubMed ID: 36824150
[TBL] [Abstract] [Full Text] [Related]
13. Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration-resistant prostate cancer.
Ke ZB; You Q; Xue YT; Sun JB; Chen JY; Liu WQ; Wei Y; Zheng QS; Li XD; Xue XY; Xu N
Cancer Med; 2023 Apr; 12(7):8251-8266. PubMed ID: 36750989
[TBL] [Abstract] [Full Text] [Related]
14. The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer.
Rusarova N; Vitaskova D; Kalabova H; Ondruskova A; Purova D; Melichar B; Studentova H
Future Oncol; 2022 Dec; 18(38):4183-4192. PubMed ID: 36519589
[TBL] [Abstract] [Full Text] [Related]
15. The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial.
Karkeet RM; Zekri AN; Sayed-Ahmed MM; Sherif GM; Salem SE; Abdelbary A; Fouad MA; Saad SY
PLoS One; 2022; 17(12):e0278282. PubMed ID: 36480560
[TBL] [Abstract] [Full Text] [Related]
16. Construction and validation of web-based nomograms for detecting and prognosticating in prostate adenocarcinoma with bone metastasis.
Dong Q; Wu X; Gan W; Mok TN; Shen J; Zha Z; Chen J
Sci Rep; 2022 Nov; 12(1):18623. PubMed ID: 36329203
[TBL] [Abstract] [Full Text] [Related]
17. [Epidemiological and clinicopathological characteristics of prostate cancer in Hunan].
Zou B; Long Y; Yang ZM; Gao RS; Lin QF; Dai XJ; Yi G; Wang QZ; Zhou Q; Zhang XB
Zhonghua Nan Ke Xue; 2022 Sep; 28(9):786-791. PubMed ID: 37839003
[TBL] [Abstract] [Full Text] [Related]
18. Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castration-resistant prostate cancer.
Yang T; Liu Y; Chen S; Tian J; Zhu X; Zhang L; Wang W; Qin Y; Richter J; Anand A; Xu C; Chi Y; Wang C; Bian C; Wu D; Li Z; Huang S
Prostate; 2022 Sep; 82(13):1284-1292. PubMed ID: 35747943
[TBL] [Abstract] [Full Text] [Related]
19. The Prognostic Value of Posttreatment
Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L
J Nucl Med; 2023 Jan; 64(1):69-74. PubMed ID: 35738906
[No Abstract] [Full Text] [Related]
20. The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant psa response under enzalutamide.
Poteska R; Rahbar K; Semjonow A; Schrader AJ; Boegemann M; Schlack K
BMC Cancer; 2022 Apr; 22(1):375. PubMed ID: 35395766
[TBL] [Abstract] [Full Text] [Related]
[Next]
